MIRM

NASDAQ · Biotechnology

Mirum Pharmaceuticals Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$92.00

+0.17 (+0.19%)

As of Sep 21, 8:35 PM ET ·

MIRM News1 articles

Mirum Surges on Volixibat Success in PSC Itch Trial, FDA Filing Targeted

Mirum Pharmaceuticals announced volixibat met its primary endpoint in a Phase 2b trial for PSC, reducing itch scores. Shares rose 9%. The company plans a pre-NDA FDA meeting this summer and a U.S. filing in H2 2026.